NEW YORK – A. Menarini Diagnostics has launched two point-of-care tests for COVID-19, including an antigen test that it believes detects not only whether a patient may be infected with SARS-CoV-2 but also provides information about how infected the individual may be.
The two immunofluorescence tests run on the company's AFIAS point-of-care platform, which has two available formats and can provide results in 12 minutes. The AFIAS 1 instrument can run one sample at a time, while the AFIAS 6 runs six samples simultaneously.